医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
25期
128-129,130
,共3页
重组人生长激素%慢性肾衰竭%T淋巴细胞
重組人生長激素%慢性腎衰竭%T淋巴細胞
중조인생장격소%만성신쇠갈%T림파세포
Human recombinant growth hormone%Chronic renal failure%Tlymphocytes
目的研究重组人生长激素(rhGH)在慢性肾衰竭(CRF)患者T淋巴细胞免疫功能中发挥的调节作用。方法选取2012年9月26日~2013年3月26日入住我院的60例慢性肾衰竭患者作为研究对象，随机分成试验组和对照组，每组各30例。治疗期间，试验组患者在常规治疗肾衰的基础上采用rhGH进行治疗，对照组采用常规治疗。患者治疗6 w后，观察治疗两组患者治疗期间的T淋巴细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)的变化以及感染的发生率。结果试验组的CD3+、CD4+、CD4+/CD8+的变化率明显有了上升的趋势，而CD8+较治疗前相比含量下降，上述指标的变化与对照组相比亦有显著性差异，有一定的统计学意义(P<0.05)。结论 rhGH可以提高CRF患者的T淋巴细胞免疫功能，从而降低患者感染的发生率，在一定程度上提高患者的生活质量。
目的研究重組人生長激素(rhGH)在慢性腎衰竭(CRF)患者T淋巴細胞免疫功能中髮揮的調節作用。方法選取2012年9月26日~2013年3月26日入住我院的60例慢性腎衰竭患者作為研究對象，隨機分成試驗組和對照組，每組各30例。治療期間，試驗組患者在常規治療腎衰的基礎上採用rhGH進行治療，對照組採用常規治療。患者治療6 w後，觀察治療兩組患者治療期間的T淋巴細胞亞群(CD3+、CD4+、CD8+、CD4+/CD8+)的變化以及感染的髮生率。結果試驗組的CD3+、CD4+、CD4+/CD8+的變化率明顯有瞭上升的趨勢，而CD8+較治療前相比含量下降，上述指標的變化與對照組相比亦有顯著性差異，有一定的統計學意義(P<0.05)。結論 rhGH可以提高CRF患者的T淋巴細胞免疫功能，從而降低患者感染的髮生率，在一定程度上提高患者的生活質量。
목적연구중조인생장격소(rhGH)재만성신쇠갈(CRF)환자T림파세포면역공능중발휘적조절작용。방법선취2012년9월26일~2013년3월26일입주아원적60례만성신쇠갈환자작위연구대상，수궤분성시험조화대조조，매조각30례。치료기간，시험조환자재상규치료신쇠적기출상채용rhGH진행치료，대조조채용상규치료。환자치료6 w후，관찰치료량조환자치료기간적T림파세포아군(CD3+、CD4+、CD8+、CD4+/CD8+)적변화이급감염적발생솔。결과시험조적CD3+、CD4+、CD4+/CD8+적변화솔명현유료상승적추세，이CD8+교치료전상비함량하강，상술지표적변화여대조조상비역유현저성차이，유일정적통계학의의(P<0.05)。결론 rhGH가이제고CRF환자적T림파세포면역공능，종이강저환자감염적발생솔，재일정정도상제고환자적생활질량。
Objective In order to study the ef ects of recombinant human growth hormone (rhGH)on regulating T lymphocytes immune function in chronic renal failure (CRF) patients . Methods Selecting 60 cases of CRF patients as the research objects who were treated at our hospital from on September 26, 2012 to March 26, 2013, then, these 60 CRF patients were randomly divided into experimental group and control group, including 30 cases in each group. During the period of treatment,the patients of experimental group were treated with rhGH on the basis of routine treatment ,however ,the control group patients were only treated with routine treatment. Six weeks after treatment ,observing two groups of patients,s the change of T lymphocyte subsets (CD3+, CD4+, CD4+to CD8+) and the incidence of infection. Results The ratio of CD3+、CD4、CD4+to CD8+ of experimental group was significantly increased while the level of CD8+remarkably decreased after treatment as compared with the control . However,the comparative dif erence which had certain statistical significance between the control group and the experimental group was significant. Conclusion rhGH can obviously improve the T lymphocyte immune function of the CRF patients. rhGH can to a certain extent reduce the incidence of infection in patients, so improve the patient's quality of life.
